论文部分内容阅读
目的:观察并评价吡柔比星为主的联合化疗方案治疗恶性肿瘤的疗效。方法:45例均为病理确诊的晚期恶性肿瘤,吡柔比星30 mg/m2~60 mg/m2,根据不同的肿瘤类型联合其他化疗药物,连续2个～6个疗程,观察疗效及毒副作用。结果:有效率为60 %,其中CR6例(13 %),PR21例(46.7 %)。毒副作用主要表现为白细胞下降,而心脏毒副反应、脱发、消化道反应均较轻微。结论:吡柔比星为主联合化疗治疗晚期恶性肿瘤疗效确切,毒副作用小,值得临床推广。
Objective: To observe and evaluate the efficacy of pirarubicin-based combination chemotherapy in the treatment of malignant tumors. Methods: Forty-five patients were pathologically confirmed advanced malignancies, with pirarubicin 30 mg / m2 ~ 60 mg / m2. The patients were treated with other chemotherapeutic agents according to different tumor types for two to six consecutive courses to observe the curative effect and side effects . Results: The effective rate was 60%, of which CR 6 cases (13%) and PR 21 cases (46.7%). Side effects of the main manifestations of leukopenia, and heart toxicity, hair loss, gastrointestinal reactions were minor. Conclusion: Pirarubicin-based combination chemotherapy for the treatment of advanced malignancies has definite curative effect and small toxic and side effects, which is worthy of clinical promotion.